<?xml version="1.0" encoding="UTF-8"?>
<p>The characteristics of the 39 MPN patients enrolled in the study are summarized in 
 <xref rid="t1-1040710" ref-type="table">Table 1</xref>. None of the patients was newly diagnosed. The median time between MPN diagnosis and trial registration was 3.6 years (range 1.6-8.6 years). Prior to inclusion, 30 patients (77%) had received cytoreductive therapy and 21 (55%) were treated by phlebotomy. Treatment with mirabegron was completed as per protocol in 32 out of 39 patients (82%). In 2 patients (5%), treatment was stopped due to toxicity, in 2 patients (5%) due to patients' preference, and in one patient (3%) due to breast cancer diagnosis (
 <xref rid="t2-1040710" ref-type="table">Table 2</xref>). Treatment deviation was described in 16 patients (41%) and was due to patient's decision (n=6; 15%), doctor's decision (n=1; 3%), toxicity (n=2; 5%) or other reasons (n=12; 31%). Thirty-six patients (92%) received concomitant medication (
 <xref rid="t2-1040710" ref-type="table">Table 2</xref>).
</p>
